Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

NCT03635021 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

419

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: FOLFOX regimen
DRUG: Panitumumab
DRUG: Bevacizumab
DRUG: FOLFIRI regimen

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators

[object Object]